Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.